Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Seid Hamzic"'
Autor:
Seid Hamzic, Stefan Aebi, Markus Joerger, Michael Montemurro, Marc Ansari, Ursula Amstutz, Carlo Largiadèr
Publikováno v:
Swiss Medical Weekly, Vol 150, Iss 4748 (2020)
Fluoropyrimidines (FPs), mainly 5-fluorouracil (5-FU) and its oral prodrug capecitabine (Cap), remain the backbone of the treatment of many different solid tumors. Despite their broad use in clinical routine, 10–40% of patients experience severe, a
Externí odkaz:
https://doaj.org/article/0ef46732bff3495b8511d835fbe22eef
Autor:
Dominic Schaerer, Tanja K. Froehlich, Seid Hamzic, Steven M. Offer, Robert B. Diasio, Markus Joerger, Ursula Amstutz, Carlo R. Largiadèr
Publikováno v:
Journal of Personalized Medicine, Vol 10, Iss 4, p 181 (2020)
Inhibition of thymidylate synthase (TS) is the primary mode of action for 5-fluorouracil (5FU) chemotherapy. TS expression is modulated by a variable number of tandem repeats in the TS enhancer region (TSER) located upstream of the TS gene (TYMS). Va
Externí odkaz:
https://doaj.org/article/c31a2db4bbd34587b4b5b7393dec8a7c
Autor:
Seid Hamzic, Richard Lewis, Sandrine Desrayaud, Cihan Soylu, Mike Fortunato, Grégori Gerebtzoff, Raquel Rodríguez-Pérez
Publikováno v:
Journal of Chemical Information and Modeling. 62:3180-3190
Assessing whether compounds penetrate the brain can become critical in drug discovery, either to prevent adverse events or to reach the biological target. Generally, pre-clinical in vivo studies measuring the ratio of brain and blood concentrations (
Autor:
Stefano Fontana, Carlo R. Largiadèr, Dominic Schärer, Stefan Schürch, Robert B. Diasio, Seid Hamzic, Christos T. Nakas, Ursula Amstutz, Didier Meulendijks, Marc Wehrli, Steven M. Offer
Publikováno v:
Hamzic, Seid; Schärer, Dominic; Offer, Steven M.; Meulendijks, Didier; Nakas, Christos; Diasio, Robert B; Fontana, Stefano; Wehrli, Marc; Schürch, Stefan; Amstutz, Ursula; Largiadèr, Carlo R. (2021). Haplotype structure defines effects of common DPYD variants c.85T > C (rs1801265) and c.496A > G (rs2297595) on dihydropyrimidine dehydrogenase activity: Implication for 5-fluorouracil toxicity. British journal of clinical pharmacology, 87(8), pp. 3234-3243. Wiley-Blackwell 10.1111/bcp.14742
British Journal of Clinical Pharmacology
British Journal of Clinical Pharmacology
AIMS The aim of this study was to identify risk variants and haplotypes that impair dihydropyrimidine dehydrogenase (DPD) activity and are, therefore, candidate risk variants for severe toxicity to 5-fluorouracil (5-FU) chemotherapy. METHODS Plasma d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e065a3410c6f5d8e92f10376d91f8964
Publikováno v:
Pharmacogenomics. 19:689-692
Autor:
N Wenger, Carlo R. Largiadèr, Tanja K. Froehlich, Stefan Aebi, Ursula Amstutz, Markus Joerger, Seid Hamzic
Publikováno v:
The Pharmacogenomics Journal. 17:319-324
A missense variant (c.1637C>T, T546M) in ABCC11 encoding the MRP8 (multidrug resistance protein 8), a transporter of 5-fluorodeoxyuridine monophosphate, has been associated with an increased risk of 5-fluorouracil-related severe leukopenia. To valida
Autor:
Markus Joerger, Tanja K. Froehlich, Jan H.M. Schellens, Didier Meulendijks, Seid Hamzic, Carlo R. Largiadèr, Claire Palles, Xandra García-González, Luis A. López-Fernández, Ursula Amstutz, Stefan Aebi, Ian Thomlinson, Dominic Kummer
Publikováno v:
Hamzic, Seid; Kummer, Dominic; Froehlich, Tanja K.; Joerger, Markus; Aebi, Stefan; Palles, Claire; Thomlinson, Ian; Meulendijks, Didier; Schellens, Jan H M; García-González, Xandra; López-Fernández, Luis A; Amstutz, Ursula; Largiadèr, Carlo R. (2020). Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: An IPD meta-analysis. Pharmacological research, 152, p. 104594. Elsevier 10.1016/j.phrs.2019.104594
To assess the proposed associations of the c.742-227G>A (rs2612091) polymorphism within the Enolase Superfamily Member 1 gene (ENOSF1) and two variants in the adjacent Thymidylate Synthase gene (TYMS): the 5'VNTR 28bp-repeat (rs45445694) and 3'UTR 6b
Autor:
Markus Joerger, Dominic Kummer, Stefan Aebi, Seid Hamzic, Carlo R. Largiadèr, Ursula Amstutz, S Milesi, D Mueller
Publikováno v:
Clinical pharmacology and therapeutics. 102(5)
An important concern with the anticancer drug capecitabine (Cp), an oral prodrug of 5‐fluorouracil, are dose‐limiting adverse effects, in particular hand‐foot syndrome (HFS) and diarrhea. Here we evaluated the association of genetic variability